Cargando…

Long-Term Antipsychotic Effectiveness and Comparison of the Efficacy of Monotherapy and Polypharmacy in Schizophrenia: A 3-Years Follow-Up “Real World” Study in China

Background: Discontinuation of antipsychotic treatment is a common problem in patients with schizophrenia and could reduce the effectiveness of treatment. Time to discontinuation (TTD) is one of the indicators of compliance and may also be an effective indicator of medication efficacy. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, He, Sidi, He, Luyao, Yu, Wenjuan, He, Shen, Li, Yange, Yu, Yimin, Zheng, Qingshan, Huang, Jingjing, Shen, Yifeng, Li, Huafang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234304/ https://www.ncbi.nlm.nih.gov/pubmed/35770081 http://dx.doi.org/10.3389/fphar.2022.860713

Ejemplares similares

Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS
por: He, Luyao, et al.
Publicado: (2022)

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
por: Yu, Wenjuan, et al.
Publicado: (2021)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
por: Fisher, Maxine D, et al.
Publicado: (2014)

Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia
por: Weng, Jiajun, et al.
Publicado: (2019)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
por: Li, Yange, et al.
Publicado: (2021)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Sex differences between serum total bilirubin levels and cognition in patients with schizophrenia
por: He, Shen, et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Two Novel Loci of RELN Associated With Antipsychotics Response in Chinese Han Population
por: Xu, Qingqing, et al.
Publicado: (2020)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study
por: Weng, Jiajun, et al.
Publicado: (2023)

Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China
por: Zhang, Lei, et al.
Publicado: (2019)

The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
por: Lee, Hee-Won, et al.
Publicado: (2013)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial
por: Huang, Jingjing, et al.
Publicado: (2021)

Plasma metabolomics of schizophrenia with cognitive impairment: A pilot study
por: Jiang, Yihe, et al.
Publicado: (2022)

Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
por: Kim, Hee-Yun, et al.
Publicado: (2014)

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
por: Ijaz, Sharea, et al.
Publicado: (2018)

Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study
por: Patrichi, Bogdan, et al.
Publicado: (2021)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens
por: Kardas, Przemysław, et al.
Publicado: (2021)

Promoter Hypomethylation of miR-124 Gene Is Associated With Major Depressive Disorder
por: Zeng, Duan, et al.
Publicado: (2021)

A Real-World Observation of Antipsychotic Effects on Brain Volumes and Intrinsic Brain Activity in Schizophrenia
por: Chen, Yifan, et al.
Publicado: (2022)

Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis
por: Hou, Liyan, et al.
Publicado: (2023)

Developments in antipsychotic therapy with regard to hypotheses for schizophrenia
por: Ackenheil, Manfred, et al.
Publicado: (2002)

Barriers and facilitators to maintaining a high level of polypharmacy adherence in people living with HIV: A scoping review
por: He, Jiamin, et al.
Publicado: (2023)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis
por: Ayenew, Wondim, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8a7jon1kpi260cogu7pcii70r